0.25
-9.95%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NextCell Pharma
Its shares trade on Nasdaq Stockholm under the ticker NXTCL.ST. It has been listed since 13 July 2017. In the fiscal year to 31 August 2025, it reported revenue of SEK 10.9m and a net loss of SEK 35.1m. At that date it held total assets of SEK 76.7m and shareholders' equity of SEK 66.4m.
NextCell Pharma AB engages in the development of stem cell products. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2017-07-13. The firm is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Jul 2017
- Website
- nextcellpharma.com ↗
Leadership
Pay as last reported
- Anders Essen-MöllerChairman, since 2014
- Mathias Svahn, PhDChief Executive Officer, since 2014
- Sofia FredriksonChief Financial Officer, since 2018
- Lindsay Davies, PhDChief Scientific Officer, since 2020
- Edvard Smith, MD, PhDDirector & Medical Manager, since 2014
- Sofie Falk JanssonDirector-Marketing & Sales, since 2018
- Edvard Smith, MD, PhDDirector & Medical Manager, since 2014
- Camilla Myhre SandbergIndependent Director, since 2017
- Hans-Peter Torsten Ekre, PhDIndependent Director, since 2014
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NextCell Pharma AB develops stem cell therapies using proprietary algorithms for autoimmune diabetes treatment.
- The company operates a tissue establishment and biobank classified as a healthcare provider.
- NextCell's focus on mesenchymal stem cell products targets autoimmune diseases with potential market demand.
Weaknesses
- NextCell Pharma AB's IPO occurred in 2017, indicating limited market experience.
- The company's business concept relies on a single product focus for autoimmune diabetes.
- NextCell's operations are based in Huddinge, Sweden, limiting geographic diversification.
Opportunities
- NextCell Pharma AB can expand its stem cell product portfolio to address additional autoimmune conditions.
- The growing healthcare sector in Sweden offers potential for increased demand for stem cell therapies.
- NextCell's biobank services may attract partnerships with research institutions.
Threats
- NextCell Pharma AB faces competition from established biotechnology firms in the Health Care sector.
- Regulatory challenges in the biotechnology industry could delay product approvals.
- The company's reliance on a single therapeutic focus poses a risk if market demand shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.